Market Research Trends

The global market for genital warts (condyloma acuminatum) is expected to be worth $1.87 billion in 2023, rising to $3 billion by 2033 at a CAGR of 4.84%. As new drugs are introduced, the dynamics of the genital warts market are expected to change in the coming years. Tamir Biotechnology (Orgenesis), Verrica Pharmaceuticals, Novan Inc., and others are developing drugs to treat genital warts. Furthermore, successful and well-communicated vaccination campaigns have raised public awareness of vaccines and their benefits, resulting in increased vaccine uptake. Furthermore, increased vaccination coverage has been linked to a decrease in genital wart occurrence. Paladin Labs Inc., a subsidiary of Endo International plc., a pharmaceutical company, announced the July 2014 launch of Veregen (sinecatechins) Ointment, 10%, a topical treatment for external genital and perianal warts (condylomata acuminata) in immunocompetent patients aged 18 and older. Furthermore, continuous innovation in the ...

The global genital warts (condyloma acuminatum) market is expected to be worth US$ 1.87 billion in 2023, rising to US$ 3 billion by 2033 at a CAGR of 4.84%. The dynamics of the genital warts market are expected to change in the coming years as new drugs are introduced. Drugs for genital warts are being developed by key players such as Tamir Biotechnology (Orgenesis), Verrica Pharmaceuticals, Novan Inc., and others. Furthermore, successful and well-communicated vaccination programmes have increased public awareness of vaccines and their benefits, leading to increased vaccine uptake. Furthermore, increased vaccination coverage has been linked to a decrease in the occurrence of genital warts. FMI, in its business report, elaborates the historical and current scenario of the global Genital Warts (Condyloma Acuminatum) Market in terms of production, consumption, volume, and value. The report scrutinizes the market into various segments, regions and players on the basis of demand pattern ...